2024
Real-World Experience and Outcomes With Percutaneous Coronary Intervention for Protected Versus Unprotected Left Main Coronary Artery Disease: Insights from the Veteran Affairs Clinical Assessment Reporting and Tracking Program
Gonzalez P, Hebbe A, Hussain Y, Khera R, Banerjee S, Plomondon M, Waldo S, Pfau S, Curtis J, Shah S. Real-World Experience and Outcomes With Percutaneous Coronary Intervention for Protected Versus Unprotected Left Main Coronary Artery Disease: Insights from the Veteran Affairs Clinical Assessment Reporting and Tracking Program. The American Journal Of Cardiology 2024, 222: 39-50. PMID: 38677666, DOI: 10.1016/j.amjcard.2024.04.039.Peer-Reviewed Original ResearchULM percutaneous coronary interventionPercutaneous coronary interventionPropensity-matched cohortMyocardial infarctionCoronary interventionAll-cause mortalityTracking programUS clinical practiceOne-year MACEOne-year outcomesIncidence of rehospitalizationAdverse cardiovascular eventsUnprotected left main coronary artery diseaseAcute coronary syndromeCoronary artery diseaseRates of MIMechanical circulatory supportLeft main percutaneous coronary interventionPCI patientsUrgent revascularizationPractice patternsCart programLeft main bifurcationPrimary outcomeMatched cohort
2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo group
2017
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack
Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation 2017, 135: 1882-1893. PMID: 28246237, PMCID: PMC5511545, DOI: 10.1161/circulationaha.116.024863.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeType 1 myocardial infarctionTransient ischemic attackMyocardial infarctionCoronary syndromeInsulin resistanceIschemic attackIschemic strokeDiabetes mellitusSerum troponinAcute coronary syndrome episodeMean age 63 yearsAcute coronary syndrome eventIndependent clinical events committeeType 2 myocardial infarctionIRIS participantsImpact of pioglitazoneRecent cerebrovascular eventsRecent ischemic strokeClinical events committeeAge 63 yearsEffect of pioglitazoneSmall myocardial infarctionCoronary artery diseaseST-segment elevation
2012
Cellularity and structure of fresh human coronary thrombectomy specimens; presence of cells with markers of progenitor cells
Jovin IS, Lei L, Huang Y, Hao Z, Curtis JP, Brennan JJ, Remetz MS, Setaro JF, Pfau SE, Howes CJ, Clancy JF, Cabin HS, Cleman MW, Giordano FJ. Cellularity and structure of fresh human coronary thrombectomy specimens; presence of cells with markers of progenitor cells. Journal Of Cellular And Molecular Medicine 2012, 16: 3022-3027. PMID: 22947374, PMCID: PMC4393730, DOI: 10.1111/j.1582-4934.2012.01629.x.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary thrombectomyCoronary syndromeProgenitor cellsCholesterol crystalsAcute myocardial infarctionEndothelial progenitor cellsFormation of thrombiHaematopoietic progenitor cellsVon Willebrand factorInflammatory cellsEndothelial cell mediumMyocardial infarctionPlaque ruptureThrombectomyImmunohistochemical analysisVascular wallPresence of cellsBlood cellsWillebrand factorThrombus
2001
Serum complement activation in congestive heart failure
Clark D, Cleman M, Pfau S, Rollins S, Ramahi T, Mayer C, Caulin-Glaser T, Daher E, Kosiborod M, Bell L, Setaro J. Serum complement activation in congestive heart failure. American Heart Journal 2001, 141: 684-690. PMID: 11275938, DOI: 10.1067/mhj.2001.113758.Peer-Reviewed Original ResearchConceptsCongestive heart failureSymptomatic heart failureC5b-9 levelsHeart failureClinical outcomesC5b-9Control patientsNew York Heart Association class IV symptomsComplement activationAge-matched control patientsClass IV symptomsCombined clinical outcomeAdverse clinical outcomesVentricular ejection fractionTerminal complement complex C5b-9Terminal complement activationComplement complex C5b-9Serum complement activationTerminal complement complexAdverse eventsCardiopulmonary bypassEjection fractionSerum levelsMyocardial injuryMyocardial infarction